197 related articles for article (PubMed ID: 29623616)
1. Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.
Rose M; Rice S; Craig D
Pharmacoecon Open; 2018 Jun; 2(2):97-107. PubMed ID: 29623616
[TBL] [Abstract][Full Text] [Related]
2. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
Tosh JC; Longworth LJ; George E
Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
[TBL] [Abstract][Full Text] [Related]
3. Single technology appraisals by NICE: are they delivering faster guidance to the NHS?
Barham L
Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204
[TBL] [Abstract][Full Text] [Related]
4. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
Meregaglia M; Nicod E; Drummond M
Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
[TBL] [Abstract][Full Text] [Related]
5. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
[TBL] [Abstract][Full Text] [Related]
6. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
7. Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers' Information Sources.
Takada S; Narukawa M
Int J Technol Assess Health Care; 2022 Mar; 38(1):e25. PubMed ID: 35297362
[TBL] [Abstract][Full Text] [Related]
8. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
[TBL] [Abstract][Full Text] [Related]
9. The impact of rarity in NICE's health technology appraisals.
Clarke S; Ellis M; Brownrigg J
Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
[TBL] [Abstract][Full Text] [Related]
10. Capturing what matters: updating NICE methods guidance on measuring and valuing health.
Dawoud D; Lamb A; Moore A; Bregman C; Rupniewska E; Paling T; Wolfram V; Lovett RES; Dent R
Qual Life Res; 2022 Jul; 31(7):2167-2173. PubMed ID: 35247152
[TBL] [Abstract][Full Text] [Related]
11. Assessment of quality of data submitted for NICE technology appraisals over two decades.
Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
[TBL] [Abstract][Full Text] [Related]
12. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
Kaltenthaler E; Papaioannou D; Boland A; Dickson R
Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
[TBL] [Abstract][Full Text] [Related]
13. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
14. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
Hale G; Morris J; Barker-Yip J
J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
[No Abstract] [Full Text] [Related]
15. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents.
Hill H; Rowen D; Pennington B; Wong R; Wailoo A
Value Health; 2020 Jul; 23(7):907-917. PubMed ID: 32762993
[TBL] [Abstract][Full Text] [Related]
17. A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process.
Walton MJ; O'Connor J; Carroll C; Claxton L; Hodgson R
Pharmacoecon Open; 2019 Sep; 3(3):403-410. PubMed ID: 30617953
[TBL] [Abstract][Full Text] [Related]
18. Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals.
Radeva D; Hopkin G; Mossialos E; Borrill J; Osipenko L; Naci H
Int J Technol Assess Health Care; 2020 Jul; ():1-6. PubMed ID: 32618536
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
